Diana Lüftner
Research Subjects
Diana Lüftner has a total of 362 co-authors. Here are the top co-authors by number of shared publications:
- Michael Patrick Lux
Klinik für Gynäkologie und Geburtshilfe, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, St. Vincenz Kliniken, Paderborn, Paderborn, Germany
10 shared publications Wolfgang Janni
Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany
10 shared publications- Peter Andreas Fasching
Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany
9 shared publications - Sara Yvonne Brucker
Department of Gynecology and Obstetrics, University Hospital Tübingen, Tübingen, Germany
9 shared publications Volkmar Müller
Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland
9 shared publicationsMichael Untch
Abteilung für Gynäkologie und Geburtshilfe, Multidisziplinäres Brustkrebszentrum und Zentrum für Gynäkologische Onkologie, HELIOS Klinikum Berlin Buch, Berlin, Deutschland
8 shared publications
Latest Publications
- 2 October 2026
- Published by Springer Nature in Die Onkologie
- Vol. 32 (11) , 1084-1089
Medikamentöse Therapie des metastasierten Mammakarzinoms
- 2 October 2026
- Published by Springer Nature in Die Onkologie
- Vol. 32 (11) , 1084-1089
Medikamentöse Therapie des metastasierten Mammakarzinoms
- Open Access
- 17 March 2026
- Published by Georg Thieme Verlag KG in Senologie - Zeitschrift für Mammadiagnostik und -therapie
- Vol. 23 (01) , 63-74
Indirect Treatment Comparison between Ribociclib Combined with Non-Steroidal Aromatase Inhibitors and Ovarian Function Suppression vs. Tamoxifen in Premenopausal Women with Early Breast Cancer
This study provides an indirect treatment comparison of ribociclib combined with non-steroidal aromatase inhibitors and ovarian function suppression (ribociclib + NSAI + OFS) vs. a frequently used treatment option in German clinical routine (tamoxifen ± OFS) in premenopausal patients with HR-positive (HR+), HER2-negative (HER2−) early breast cancer (BC). Data on premenopausal women treated with ribociclib and tamoxifen were derived from the NATALEE clinical trial (NCT03701334) and the retrospective German data collection CLEAR-B, respectively. NATALEE trial eligibility criteria were applied to the CLEAR-B dataset. Standardized mortality ratio weights were used for propensity score (PS) adjustment to balance study populations. All hazard ratios (HR) were calculated based on a 4-year-observation period for both treatment arms. Effectiveness endpoints comprised invasive and distant disease-free survival (iDFS, dDFS), recurrence-free survival (RFS), and overall survival (OS). Safety-related endpoints were treatment termination (TT) and toxicity-related TT (TTtox). For safety comparisons, the ribociclib arm was divided into groups that discontinued ribociclib + NSAI + OFS or ribociclib only. Significant beneficial effects favoring ribociclib + NSAI + OFS (n = 1115) over tamoxifen ± OFS (n = 822) were observed for all effectiveness outcomes (iDFS [HR = 0.5 (95% CI 0.35; 0.71); p < 0.01]; dDFS [HR = 0.52 (95% CI 0.35; 0.77); p = 0.01], RFS [HR = 0.42 (95% CI 0.29; 0.62); p < 0.01], OS [HR = 0.34 (95% CI 0.18; 0.63); p = 0.01]) during the 4-year-observation period. The effect of early treatment discontinuation showed no significant differences between ribociclib + NSAI + OFS and tamoxifen ± OFS (TT-a: HR = 1.2 [95% CI: 0.71; 2.01], p = 0.48; TTtox-a: HR = 0.54 [95% CI 0.22; 1.30], p = 0.23). In this retrospective analysis, ribociclib + NSAI + OFS demonstrated advantages across all effectiveness endpoints, including OS, in premenopausal women with HR+, HER2− early BC, without increasing overall treatment discontinuation rates compared to tamoxifen ± OFS.
- 17 March 2026
- Published by Georg Thieme Verlag KG in Senologie - Zeitschrift für Mammadiagnostik und -therapie
- Vol. 23 (01) , 63-74
Open AccessIndirect Treatment Comparison between Ribociclib Combined with Non-Steroidal Aromatase Inhibitors and Ovarian Function Suppression vs. Tamoxifen in Premenopausal Women with Early Breast Cancer
This study provides an indirect treatment comparison of ribociclib combined with non-steroidal aromatase inhibitors and ovarian function suppression (ribociclib + NSAI + OFS) vs. a frequently used treatment option in German clinical routine (tamoxifen ± OFS) in premenopausal patients with HR-positive (HR+), HER2-negative (HER2−) early breast cancer (BC). Data on premenopausal women treated with ribociclib and tamoxifen were derived from the NATALEE clinical trial (NCT03701334) and the retrospective German data collection CLEAR-B, respectively. NATALEE trial eligibility criteria were applied to the CLEAR-B dataset. Standardized mortality ratio weights were used for propensity score (PS) adjustment to balance study populations. All hazard ratios (HR) were calculated based on a 4-year-observation period for both treatment arms. Effectiveness endpoints comprised invasive and distant disease-free survival (iDFS, dDFS), recurrence-free survival (RFS), and overall survival (OS). Safety-related endpoints were treatment termination (TT) and toxicity-related TT (TTtox). For safety comparisons, the ribociclib arm was divided into groups that discontinued ribociclib + NSAI + OFS or ribociclib only. Significant beneficial effects favoring ribociclib + NSAI + OFS (n = 1115) over tamoxifen ± OFS (n = 822) were observed for all effectiveness outcomes (iDFS [HR = 0.5 (95% CI 0.35; 0.71); p < 0.01]; dDFS [HR = 0.52 (95% CI 0.35; 0.77); p = 0.01], RFS [HR = 0.42 (95% CI 0.29; 0.62); p < 0.01], OS [HR = 0.34 (95% CI 0.18; 0.63); p = 0.01]) during the 4-year-observation period. The effect of early treatment discontinuation showed no significant differences between ribociclib + NSAI + OFS and tamoxifen ± OFS (TT-a: HR = 1.2 [95% CI: 0.71; 2.01], p = 0.48; TTtox-a: HR = 0.54 [95% CI 0.22; 1.30], p = 0.23). In this retrospective analysis, ribociclib + NSAI + OFS demonstrated advantages across all effectiveness endpoints, including OS, in premenopausal women with HR+, HER2− early BC, without increasing overall treatment discontinuation rates compared to tamoxifen ± OFS.
- 10 December 2025
- Published by Springer Nature in Die Onkologie
- Vol. 32 (1) , 100-109
Medikamentöse Therapie des frühen Mammakarzinoms
- 10 December 2025
- Published by Springer Nature in Die Onkologie
- Vol. 32 (1) , 100-109
Medikamentöse Therapie des frühen Mammakarzinoms
- Open Access
- 31 July 2025
- Published by Springer Nature in Die Onkologie
- Vol. 31 (8) , 733-736
Molekularpathologie und Antikörper-Wirkstoff-Konjugate
- 31 July 2025
- Published by Springer Nature in Die Onkologie
- Vol. 31 (8) , 733-736
Open AccessMolekularpathologie und Antikörper-Wirkstoff-Konjugate
- Open Access
- 4 April 2025
- Published by Georg Thieme Verlag KG in Geburtshilfe und Frauenheilkunde
- Vol. 85 (06) , 599-610
Indirect Treatment Comparison between Ribociclib Combined with Non-Steroidal Aromatase Inhibitors and Ovarian Function Suppression vs. Tamoxifen in Premenopausal Women with Early Breast Cancer
This study provides an indirect treatment comparison of ribociclib combined with non-steroidal aromatase inhibitors and ovarian function suppression (ribociclib + NSAI + OFS) vs. a frequently used treatment option in German clinical routine (tamoxifen ± OFS) in premenopausal patients with HR-positive (HR+), HER2-negative (HER2−) early breast cancer (BC). Data on premenopausal women treated with ribociclib and tamoxifen were derived from the NATALEE clinical trial (NCT03701334) and the retrospective German data collection CLEAR-B, respectively. NATALEE trial eligibility criteria were applied to the CLEAR-B dataset. Standardized mortality ratio weights were used for propensity score (PS) adjustment to balance study populations. All hazard ratios (HR) were calculated based on a 4-year-observation period for both treatment arms. Effectiveness endpoints comprised invasive and distant disease-free survival (iDFS, dDFS), recurrence-free survival (RFS), and overall survival (OS). Safety-related endpoints were treatment termination (TT) and toxicity-related TT (TTtox). For safety comparisons, the ribociclib arm was divided into groups that discontinued ribociclib + NSAI + OFS or ribociclib only. Significant beneficial effects favoring ribociclib + NSAI + OFS (n = 1115) over tamoxifen ± OFS (n = 822) were observed for all effectiveness outcomes (iDFS [HR = 0.5 (95% CI 0.35; 0.71); p < 0.01]; dDFS [HR = 0.52 (95% CI 0.35; 0.77); p = 0.01], RFS [HR = 0.42 (95% CI 0.29; 0.62); p < 0.01], OS [HR = 0.34 (95% CI 0.18; 0.63); p = 0.01]) during the 4-year-observation period. The effect of early treatment discontinuation showed no significant differences between ribociclib + NSAI + OFS and tamoxifen ± OFS (TT-a: HR = 1.2 [95% CI: 0.71; 2.01], p = 0.48; TTtox-a: HR = 0.54 [95% CI 0.22; 1.30], p = 0.23). In this retrospective analysis, ribociclib + NSAI + OFS demonstrated advantages across all effectiveness endpoints, including OS, in premenopausal women with HR+, HER2− early BC, without increasing overall treatment discontinuation rates compared to tamoxifen ± OFS.
- 4 April 2025
- Published by Georg Thieme Verlag KG in Geburtshilfe und Frauenheilkunde
- Vol. 85 (06) , 599-610
Open AccessIndirect Treatment Comparison between Ribociclib Combined with Non-Steroidal Aromatase Inhibitors and Ovarian Function Suppression vs. Tamoxifen in Premenopausal Women with Early Breast Cancer
This study provides an indirect treatment comparison of ribociclib combined with non-steroidal aromatase inhibitors and ovarian function suppression (ribociclib + NSAI + OFS) vs. a frequently used treatment option in German clinical routine (tamoxifen ± OFS) in premenopausal patients with HR-positive (HR+), HER2-negative (HER2−) early breast cancer (BC). Data on premenopausal women treated with ribociclib and tamoxifen were derived from the NATALEE clinical trial (NCT03701334) and the retrospective German data collection CLEAR-B, respectively. NATALEE trial eligibility criteria were applied to the CLEAR-B dataset. Standardized mortality ratio weights were used for propensity score (PS) adjustment to balance study populations. All hazard ratios (HR) were calculated based on a 4-year-observation period for both treatment arms. Effectiveness endpoints comprised invasive and distant disease-free survival (iDFS, dDFS), recurrence-free survival (RFS), and overall survival (OS). Safety-related endpoints were treatment termination (TT) and toxicity-related TT (TTtox). For safety comparisons, the ribociclib arm was divided into groups that discontinued ribociclib + NSAI + OFS or ribociclib only. Significant beneficial effects favoring ribociclib + NSAI + OFS (n = 1115) over tamoxifen ± OFS (n = 822) were observed for all effectiveness outcomes (iDFS [HR = 0.5 (95% CI 0.35; 0.71); p < 0.01]; dDFS [HR = 0.52 (95% CI 0.35; 0.77); p = 0.01], RFS [HR = 0.42 (95% CI 0.29; 0.62); p < 0.01], OS [HR = 0.34 (95% CI 0.18; 0.63); p = 0.01]) during the 4-year-observation period. The effect of early treatment discontinuation showed no significant differences between ribociclib + NSAI + OFS and tamoxifen ± OFS (TT-a: HR = 1.2 [95% CI: 0.71; 2.01], p = 0.48; TTtox-a: HR = 0.54 [95% CI 0.22; 1.30], p = 0.23). In this retrospective analysis, ribociclib + NSAI + OFS demonstrated advantages across all effectiveness endpoints, including OS, in premenopausal women with HR+, HER2− early BC, without increasing overall treatment discontinuation rates compared to tamoxifen ± OFS.
- 17 March 2025
- Published by Springer Nature in Die Onkologie
- Vol. 31 (8) , 800-805
Interdisziplinäres Therapiemanagement von Antikörper-Wirkstoff-Konjugaten beim rezidivierten Ovarialkarzinom
- 17 March 2025
- Published by Springer Nature in Die Onkologie
- Vol. 31 (8) , 800-805
Interdisziplinäres Therapiemanagement von Antikörper-Wirkstoff-Konjugaten beim rezidivierten Ovarialkarzinom
- Open Access
- 28 October 2024
- Published by Springer Nature in Die Onkologie
- Vol. 30 (11) , 997-999
Viel erreicht und noch viel zu tun: Patient:innenpartizipation
- 28 October 2024
- Published by Springer Nature in Die Onkologie
- Vol. 30 (11) , 997-999
Open AccessViel erreicht und noch viel zu tun: Patient:innenpartizipation
- 13 September 2024
- Published by Springer Nature in Die Onkologie
- Vol. 30 (10) , 966-973
ABC7-Konsens zur Systemtherapie des fortgeschrittenen Mammakarzinoms
- 13 September 2024
- Published by Springer Nature in Die Onkologie
- Vol. 30 (10) , 966-973
ABC7-Konsens zur Systemtherapie des fortgeschrittenen Mammakarzinoms
- 22 May 2024
- Published by Springer Nature in Die Onkologie
- Vol. 30 (7) , 628-630
Verzicht auf Sentinel-Lymphknoten-Biopsie beim frühen Mammakarzinom: bald neuer Standard?
- 22 May 2024
- Published by Springer Nature in Die Onkologie
- Vol. 30 (7) , 628-630
Verzicht auf Sentinel-Lymphknoten-Biopsie beim frühen Mammakarzinom: bald neuer Standard?
- Open Access
- 24 April 2024
- Published by Springer Nature in Die Onkologie
- Vol. 30 (6) , 513
Erratum zu: Neue Strategien beim metastasierten, endokrin sensitiven Mammakarzinom
- 24 April 2024
- Published by Springer Nature in Die Onkologie
- Vol. 30 (6) , 513
Open AccessErratum zu: Neue Strategien beim metastasierten, endokrin sensitiven Mammakarzinom